USPTO serial 99195323
V V
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- MAHMOUDI, MARIAM AZIZ
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with V V?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,844*
Plus Government fees of $900
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jeffersonville, IN, US
JEFFERSONVILLE, IN, US
JEFFERSONVILLE, IN, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Larry L. Coats
Larry L. Coats Coats & Bennett, PLLC1400 Crescent GreenSuite 300Cary, NC 27518Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business management and administration of pharmacy reimbursement programs; Managing and administering the distribution of prescription pharmaceutical samples to physicians and patients for pharmaceutical manufacturers; Mail-order pharmacy services; Business management and administration of patient co-pay reimbursement programs on behalf of pharmaceutical manufacturers; Business management and administration of financial assistance programs that provide patients with access to affordable medicine, namely, business management and administration of enrollment and reimbursement programs for the purchase of medication and generally facilitating access to medications; Business management and administration of patient support programs for pharmaceutical manufacturers; Business management and administration of patient engagement programs for pharmaceutical manufacturers; Business management and administration of formulary, patient, and payer policy information for pharmaceutical, medical device, and diagnostic manufacturers; Business management and administration of educational engagements for health care providers, namely, business management and administration of programs to educate healthcare providers on medications, disease status and standard of care; Logistics management of the distribution of clinical trial medication and supplies on behalf of pharmaceutical manufacturers; Providing business marketing information, namely, tracking pharmaceutical promotional programs for pharmaceutical manufacturers and evaluating and determining their effectiveness; Data management services in the field of pharmaceutical patient safety, namely, collection and compilation of adverse product events information into computer databases and reporting collected adverse product events information for business purposes; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, promoting awareness of diseases, pharmaceutical brands, and affordable treatment options; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, marketing services in the nature of promotion of pharmaceutical manufacturers and disease treatment options via social media; Business information services, namely, tracking payer coverage policies and related documentation and providing life sciences clients access to such for commercial purposes in order to enhance their market access strategies and patient support programs; Business strategy consulting services for assisting life sciences clients with commercial assessments, corporate and portfolio strategy, new product planning and commercialization support, and pricing and market access insights; Business assistance services, namely, enrolling patients of pharmaceutical manufacturers into support programs that enable patients to view, track, and manage the support program wherein the patient support program provides pharmaceutical consumer product information, payer coverage status updates, and providing business information regarding access to enrollment and reimbursement programs for the purchase of medications; Providing business information and news to the pharmaceutical and life sciences industries on legislative and regulatory developments as it impacts and relates to the pharmaceutical and life sciences industries within the copay or patient affordability space | ACTIVE | — |
| 036 | Payment services, namely, reimbursement payment processing in the field of pharmaceutical financial assistance programs and loyalty program payment processing services provided on behalf of pharmaceutical manufacturers for the purpose of delivering benefits to patients enrolled in pharmaceutical manufacturer-sponsored financial assistance programs; Pharmacy benefit management services, namely, loss mitigation services and detecting claim activity indicative of a pharmacy benefit manager attempting to abuse the use of co-pay cards by not applying amounts paid by clients towards the patient's deductible or annual out-of-pocket expense; Anti-kickback and risk mitigation services for the pharmaceutical industry, namely, financial and insurance risk management for assuring that patients who have full or partial federally funded drug coverage are excluded from utilizing co-pay cards | ACTIVE | — |
| 041 | Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, providing podcasts, seminars, workshops, and virtual and in-person presentations for educational purposes in the field of diseases, pharmaceutical brands, and affordable healthcare options; Educational services, namely, conducting programs in the fields of drug therapy, side effect management, lifestyle management, disease state management and proper administration of medication; Educational services, namely, providing clinical support programs regarding drug therapy, side effect management, disease state management and proper administration of medication | ACTIVE | — |
| 042 | Quality assurance and quality control for others in the field of patient claim services for monitoring paid claims to patients from insurance or pharmaceutical entities to insure that specific business rules are being correctly applied to patient claims; Pharmacovigilance services for others, namely, scientific research and analysis pertaining to adverse events and product quality complaints regarding pharmaceutical products, evaluation and analysis of scientific data pertaining to the assessment of health risks presented by certain pharmaceutical products or combinations thereof, and product safety testing and consultation related thereto in the field of pharmaceuticals; Pharmacovigilance services for others, namely, monitoring the efficacy of pharmaceutical preparations for quality control purposes; Providing online non-downloadable software for patient support services, namely, for enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services including injection and product educational training, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications; Data warehousing services; Database development services, namely, developing databases for collecting and maintaining patient information and registry data; Database development services, namely, developing databases for customized data collection and maintaining information in the field of prescription drugs; Software as a service (SAAS) services, namely, hosting software for use by others for the purpose of connecting clinical programs with specialty drug manufacturers, and managing inventory, billing and account receivables, as well as for facilitating shipping, master patient data aggregation and analysis, and for operating and managing telephone call centers; Developing customized software for others for the purpose of connecting clinical programs with specialty drug manufacturers, and managing inventory, billing and account receivables, as well as managing shipping, master patient data aggregation and analysis, and for operating and managing telephone call centers | ACTIVE | — |
| 044 | Medical counseling in the field of drug therapy, side effect management, disease state management and proper administration of medication; Pharmaceutical consultation in the field of new specialty drugs; Providing information to patients in the field of administering medications; Providing medical information to patients; Patient health care counseling and advice regarding products in the field of prescription drugs; Providing medical information in the field of prescription drugs distributed via the Internet; Specialty pharmacy services in the nature of pharmaceutical advice and dispensing of pharmaceuticals | ACTIVE | — |
| 045 | Pharmacy benefit fraud monitoring, namely, investigation services related to pharmacy benefit insurance claims; Personal lifestyle consulting services; Providing patient advocate and case management services, namely, coordinating the procurement and administration of medication; Providing emotional counseling and emotional support services for medical patients | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Phantom Purchaser, Inc.
- Other trademarks owned by VALERIS, INC.
- Other trademarks owned by VALERIS, INC.
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named V V
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 14, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 14, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 14, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 14, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 21, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 24, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 24, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 18, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 2, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 29, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 29, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 29, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 30, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 22, 2025 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 22, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 17, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 21, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 21, 2025 | NWAP | NEW APPLICATION ENTERED | — |